Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, according to a study published in the June 6 issue of the New England Journal of Medicine.
Myriam Chalabi, M.D., Ph.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues conducted a phase 2 study involving patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer treated with neoadjuvant nivolumab plus ipilimumab. Safety, defined by timely surgery, and three-year disease-free survival were the two primary end points.
The researchers found that 113 of the 115 enrolled patients underwent timely surgery; two had surgery delayed by more than two weeks. In five patients (4 percent), grade 3 or 4 immune-related adverse events occurred; no patients discontinued treatment due to adverse events. A pathological response occurred in 98 percent of the 111 patients included in the efficacy analysis, including 95 and 68 percent with a major pathological response and a pathological complete response, respectively (defined as ≤10 and 0 percent residual viable tumor). No patients had disease recurrence during a median follow-up of 26 months.
"The high proportion of patients with a pathological response observed after only four weeks of treatment in our study, together with the safety profile, may provide sufficient justification to provide immunotherapy to patients with radiographically assessed high-risk disease, especially if three-year disease-free survival data from this study are positive," the authors write.
The study was funded by Bristol Myers Squibb, the manufacturer of nivolumab and ipilimumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Accelerated Aging Linked to Increased Odds of Preneoplastic Polyps in the Colon
TUESDAY, Dec. 17, 2024 -- Accelerated aging is associated with increased odds of harboring preneoplastic polyps (PNP) in the colon, according to a study published online Dec. 10...
Clinical Practice Guideline Updated for Radiation Therapy for Rectal Cancer
WEDNESDAY, Dec. 11, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Nov. 25 in Practical Radiation Oncology...
Screening Primary Driver of Averted Cancer Deaths From 1975 to 2020
TUESDAY, Dec. 10, 2024 -- Over the past 45 years, cancer prevention and screening accounted for most cancer deaths averted for breast, cervical, colorectal, lung, and prostate...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.